Competing interests
T.K.C. reports institutional and/or personal, paid and/or unpaid support for research, advisory boards, consultancy and/or honoraria past 10 years, ongoing or not, from Alkermes, Arcus Biosciences, AstraZeneca, Aravive, Aveo, Bayer, Bristol Myers Squibb, Bicycle Therapeutics, Calithera, Caris, Circle Pharma, Deciphera Pharmaceuticals, Eisai, EMD Serono, Exelixis, GlaxoSmithKline, Gilead, HiberCell, IQVA, Infinity, Institut Servier, Ipsen, Janssen, Kanaph, Lilly, Merck, Nikang, Neomorph, Nuscan/PrecedeBio, Novartis, Oncohost, Pfizer, Roche, Sanofi/Aventis, Scholar Rock, Surface Oncology, Takeda, Tempest, Up-To-Date, CME and non-CME events (Mashup Media Peerview, OncLive, MJH, CCO and others) and Xencor (outside the submitted work); reports institutional patents filed on molecular alterations and immunotherapy response/toxicity, rare genitourinary cancers and ctDNA/liquids biopsies; reports equity in Abalytics, CureResponse, Faron Pharma, InnDura Therapeutics, Osel, Pionyr, Precede Bio, Primium and Tempest; reports serving on committees for ACCRU, ASCO (BOD 6/2024-), ESMO, GU steering committee, KidneyCan and NCCN; reports medical writing and editorial assistance support that may have been funded by communications companies in part; reports mentorship of several non-US citizens on research projects with potential funding (in part) from non-US sources/foreign components; reports that the institution (Dana-Farber Cancer Institute) may have received additional independent funding of drug companies or/and royalties potentially involved in research around the subject matter; reports support in part by the Dana-Farber/Harvard Cancer Center Kidney SPORE (2P50CA101942−16) and Program 5P30CA006516-56, the Kohlberg Chair at Harvard Medical School and the Trust Family, Michael Brigham, Pan Mass Challenge, Hinda and Arthur Marcus Fund, Roger and Kathy Marino Fund for Research Acceleration, Frank Shaughnessy Kidney Cancer Research Fund and Loker Pinard Funds for Kidney Cancer Research at the Dana-Farber Cancer Institute. J.M. has served as a consultant, advisor and/or has received research funding or royalties from Arcus Biosciences, BioNTech, Corvus Pharmaceuticals, DynamiCure Biotechnology, Eisai, Exelixis, Genentech/Roche, IMUGENE, Kalivir Immunotherapeutics, Merck, ModeX Therapeutics, Peloton Therapeutics, Replimune, Rubius Therapeutics, Seattle Genetics/Astellas, SillaJen, Tizona Therapeutics, Tocagen, Trishula Therapeutics, Tubulis, UpToDate and Vyriad. A.P. has served as a consultant, advisor, speaker and/or has received research funding or honoraria from 1200 Pharma, AADi, AbbVie, Alpine Immune Sciences, Ambrx, Amgen, Arcus Biosciences, Arcus Ventures, Astellas Pharma, Bayer, BioNTech, BioTheryX, Bolt Biotherapeutics, Bristol Myers Squibb, Carrick Therapeutics, Compugen, Corvus Pharmaceuticals, Daiichi Sankyo, Ensem, Exelixis, Five Prime Therapeutics, Fochon Pharmaceuticals, Forty Seven, Genentech, Gilead Sciences, HalioDx, IGM Biosciences, Infinity Pharmaceuticals, Institut de Recherches Internationales Servier, Ionova, Janssen, Klus Pharma, KSQ Therapeutics, Livzon, Lilly, Loxo, Loxo@Lilly, Merck, MOMA Therapeutics, Moderna Therapeutics, Nektar, NiKang Therapeutics, Novartis, Olema Oncology, Pfizer, Pieris Pharmaceuticals, Plexxikon, Pionyr, Prelude Therapeutics, Pyrotech Therapeutics, Quanta Therapeutics, Roche, Sanofi, Scorpion Therapeutics, Seagen, Silverback Therapeutics, Surface Oncology, Symphogen, Syndax, Texas Society of Clinical Oncology (TxSCO), Upsher-Smith, Vigeo Therapeutics and Vividion Therapeutics. A.D. has served as a consultant, advisor and/or has received research funding, honoraria or other compensation from Alimera Sciences, AstraZeneca, Athos Therapeutics, Attica Sciences, AVEO, Bristol Myers Squibb, Daiichi Sankyo, Dyania Health, EMD Serono, Exelixis, Genentech/Roche, Immunomedics/Gilead, Infinity Pharmaceuticals, Janssen, Jounce Therapeutics, Kite/Gilead, Lilly, Loxo/Lilly, Merck, Merck Sharp & Dohme, Moderna Therapeutics, PACT Pharma, Pfizer, Proteas Bioanalytics, RADMETRIX, Roche/Genentech, Seattle Genetics/Astellas, Seagen and Urogen Pharma. B.I.R. has served as a consultant, advisor and/or has received research funding, leadership roles or travel support from Adela, Arcus Biosciences, AstraZeneca/MedImmune, AVEO, Bristol Myers Squibb, Eisai, Exelixis, Formedics, HiberCell, Janssen, Merck, Pfizer and Roche/Genentech. S.Y.R. has served on an advisory board/steering committee for Amgen, Astellas, AstraZeneca, BeOne, Bristol Myers Squibb, Boehringer Ingelheim, Daiichi Sankyo, Indivumed, LG Biochem, MSD, Ono Pharmaceuticals and as an invited speaker for Amgen, AstraZeneca, Astellas, BeOne, Bristol Myers Squibb, Daiichi Sankyo, MSD and Ono Pharmaceuticals. J.L.L. has served as a consultant, advisor and/or has received research funding, honoraria or stock ownership from Amgen, Arcus Biosciences, Astellas Pharma, AstraZeneca, AstraZeneca/MedImmune, Bayer Schering Pharma, Bristol Myers Squibb, Daiichi Sankyo/Astra Zeneca, Eutilex, GI Innovation, Janssen, Johnson & Johnson/Janssen, Karyopharm Therapeutics, LG Chem, Loxo/Lilly, Merck, Merck KGaA, MSD, Novartis, Oscotec, Pfizer, Roche/Genentech, Seagen and Zymeworks. M.C.O. has served as a consultant, advisor, speaker and/or has received research funding or travel support from Arcus Biosciences, Aravive, Astellas Medivation, AstraZeneca/MedImmune, AVEO, Bristol Myers Squibb Foundation, Bristol Myers Squibb, Eisai, Exelixis, HiberCell, Merck, Pfizer and Surface Oncology. R.K. has served as a speaker for Pfizer and as an advisor for EMD Serono and Springworks Therapeutics. C.H. has served as a consultant, advisor, speaker and/or has received research funding, travel support or stock ownership from Adcentrx, Astellas Pharma, AstraZeneca, Bayer, Dava Oncology, Dendreon, Exelixis, Fujifilm, Genentech, Hengrui Pharmaceutical, Janssen Oncology, Johnson & Johnson, Johnson & Johnson/Janssen, Merck, MJH Life Sciences/OncLive, OncLive/MJH Life Sciences, Pfizer, Scholar Rock, Seagen, Shionogi and Taiho Oncology. Y.S. has served as a consultant, advisor and/or has received honoraria or travel support from AVEO, Castle Biosciences and Immunocore. S.H.P. has served as a consultant, advisor and/or has received honoraria or research funding from Janssen Oncology, Merck, Merck Sharp & Dohme, Ono Pharmaceutical and Pfizer. P.C.B. has served as a consultant, advisor, speaker and/or has received research funding, honoraria or stock ownership from Astellas Medivation, AstraZeneca, AVEO, Bayer, Blue Earth Diagnostics, Bristol Myers Squibb, Caris Life Sciences, Dendreon, Eisai, EMD Serono, Exelixis, Ipsen, Luminate Medical, Medscape, Merck, Novartis, Pfizer, Pfizer/Astellas, Sumitomo and UroToday. B.A.M. reports personal fees from Arcus, grants and personal fees from Aveo, personal fees from AstraZeneca, grants and personal fees from Bayer, grants and personal fees from Bristol Myer Squibb, grants and personal fees from Daiichi, personal fees from Eisai, grants and personal fees from Exelixis, personal fees from Genmab, grants and personal fees from Gilead, personal fees from Hexagon, personal fees from Lilly and grants and personal fees from Pfizer outside the submitted work. R.R.M. has served as a consultant, advisor and/or has received research funding or honoraria from Ambrx, Arcus Biosciences, Astellas Medivation, AstraZeneca, Bayer, Blue Earth Diagnostics, Bristol Myers Squibb, Calithera Biosciences, Caris Life Sciences, Daiichi Sankyo, Dendreon, Eisai, Exelixis, Janssen, Lilly, Merck, Myovant Sciences, NeoMorph, Novartis, Oncternal Therapeutics, Pfizer, Precede Bio, Sanofi, Seagen, Sorrento Therapeutics, Sumitomo Pharma Oncology, Tempus, Telix Pharmaceuticals, Vividion Therapeutics and Artera. P.F., J.C., M.E., H.C., B.W., Y.G., J.S., A.K., S.C., R.M. and O.K. are employees of Arcus Biosciences and may own stock and/or stock options.
